---
title: 'Myeloid-derived suppressor cells in peripheral blood as predictive biomarkers
  in patients with solid tumors undergoing immune checkpoint therapy: systematic review
  and meta-analysis'
date: '2024-06-10'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38855104/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240610182540&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: Our findings suggest that standardized assessment of MDSC,
  particularly M-MDSC, should be integral to ICI therapy strategies. These cells hold
  the promise of identifying patients at risk of poor response to ICI therapy, enabling
  tailored treatment approaches. Further research focusing on the standardization
  of markers and validation of cutoff methods is crucial for integrating MDSC into
  clinical ...'
disable_comments: true
---
CONCLUSIONS: Our findings suggest that standardized assessment of MDSC, particularly M-MDSC, should be integral to ICI therapy strategies. These cells hold the promise of identifying patients at risk of poor response to ICI therapy, enabling tailored treatment approaches. Further research focusing on the standardization of markers and validation of cutoff methods is crucial for integrating MDSC into clinical ...